Aligos Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $629 | $1,269 | $1,061 | $986 |
Gross Profit | 629 | 1,269 | 451 | 312 |
EBITDA | -19,892 | -19,464 | -26,414 | -21,372 |
EBIT | -20,563 | -20,131 | -27,024 | -22,046 |
Net Income | -82,150 | -19,259 | 5,061 | -34,863 |
Net Change In Cash | 629 | 1,269 | 1,061 | 986 |
Free Cash Flow | -18,431 | -20,127 | -19,500 | -22,815 |
Cash | 36,997 | 35,331 | 45,148 | 24,367 |
Basic Shares | 6,264 | 6,272 | 3,092 | 3,092 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $3,945 | $15,529 | $13,907 | $4,359 |
Gross Profit | 3,945 | 12,460 | 13,907 | 4,359 |
EBITDA | -89,154 | -85,058 | -93,905 | -124,543 |
EBIT | -88,127 | -97,580 | -128,321 | |
Net Income | -131,211 | -87,679 | -96,046 | -128,332 |
Net Change In Cash | 3,945 | 15,529 | 13,907 | 4,359 |
Cost of Revenue | -105,518 | -33,963 | ||
Free Cash Flow | -80,873 | -79,016 | -80,332 | -116,554 |
Cash | 36,997 | 135,704 | 81,347 | 186,816 |
Basic Shares | 6,264 | 24,873 | 42,695 | 39,855 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$13.10 |
2024-09-30 | -$3.07 |
2024-06-30 | $0.03 |
2024-03-31 | -$0.22 |
